Abstracts tagged "rheumatoid arthritis"

Abstract Number: 982 • 2019 ACR/ARP Annual Meeting
A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice
Ruth Napier¹, Emily Vance ¹, James O'Dell ², Jill Poole ³, Bryant England ⁴, Michael Duryee ³, Ted Mikuls ², Holly Rosenzweig ⁵ and Geoffrey Thiele ², ¹Oregon Health & Science University and Portland VA Hospital, Portland, OR, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, ⁵Oregon Health & Science University and Portland VA Hospital, Oregon
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests in a chronic and debilitating polyarthritis. Although the etiology of RA is unknown pathogenic…
Abstract Number: 1382 • 2019 ACR/ARP Annual Meeting
The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients
Jacob Greenmyer ¹, John Stacy ¹, James Beal ², Abe Sahmoun ² and Erdal Diri¹, ¹University of North Dakota, School of Medicine Health Sciences, Minot, ND, ²University of North Dakota, School of Medicine Health Sciences, Grandforks, ND
Background/Purpose: Glucocorticoids (GCs) are commonly used in RA patients as remission induction monotherapy or as bridging therapy when starting DMARD/biologic therapy. Despite the ubiquity of…
Abstract Number: 1996 • 2019 ACR/ARP Annual Meeting
Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast
Ra Ham Kim¹, Hyun Jung Yoo ², Shin Eui Kang ³, Ji soo Park ⁴, Seon Uk Kim ⁵, Eun Young Lee ⁶, Jin Kyun Park ⁶ and Yeong-Wook Song ⁷, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Repulbic of Korea, Seoul, Republic of Korea, ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine, Seoul National University, Seoul, Republic of Korea, Seoul, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Republic of Korea, ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Republic of Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ⁷Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder, characterized by joint inflammation and bone destruction. The fibroblast-like synoviocyte(FLS) contributes to the pathogenesis of RA…
Abstract Number: 2376 • 2019 ACR/ARP Annual Meeting
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
Zoe Brown ¹, Robert Metcalf ², Jana Bednarz ³, Christiana Stavrou ⁴, Llewellyn Spargo ², Michael James ² and Susanna Proudman⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, Australia, ⁴University College London Hospital, London, United Kingdom, ⁵University of Adelaide, Adelaide, Australia
Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated…
Abstract Number: 296 • 2019 ACR/ARP Annual Meeting
Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study
Diana Vossen ¹, Valentin Schaefer², Florian Recker ³, Isabelle Geffken ⁴, Eva Matuschek ⁵ and Wolfgang Hartung ⁶, ¹Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ²Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn, Bonn, Germany, ³1. Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn and 2. Department for Obstetrics and Gynecology, University Hospital Bonn, Bonn, Germany, ⁴Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St.Elisabeth Hospital, Düsseldorf, Germany, ⁵Department for Internal Medicine, Dreifaltigkeits-Krankenhaus Wesseling, bonn, Germany, ⁶Rheumatology und clinical Immunology, Asklepios Klinik, 93077 Bad Abbach, Bad Abbach, Germany
Background/Purpose: Musculoskeletal ultrasound is an important imaging method in the diagnosis of arthritis, especially rheumatoid arthritis (RA). The prevalence of elbow joint arthritis in RA…
Abstract Number: 529 • 2019 ACR/ARP Annual Meeting
Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators
Stephen Hall¹, Tsutomu Takeuchi ², Glen Thomson ³, Paul Emery ⁴, Bernard Combe ⁵, Andrea Everding ⁶, Karel Pavelka ⁷, Yanna Song ⁸, Tim Shaw ⁹, Alan Friedman ⁹, In-Ho Song ¹⁰ and Eduardo Mysler ¹¹, ¹Monash University and Emeritus Research, Melbourne, Australia, ²Keio University School of Medicine, Tokyo, Japan, ³CIADS Research, Winnipeg, Canada, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵CHU Montpellier, Montpellier University, Montpellier, France, ⁶HRF Hamburger Rheuma Forschungszentrum, Hamburg, Germany, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁸AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁹AbbVie Inc., North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ¹¹Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: Across all phase 3 studies, treatment with upadacitinib (UPA), a JAK1-selective inhibitor, was associated with significantly higher remission (REM) rates, compared to placebo (PBO)…
Abstract Number: 983 • 2019 ACR/ARP Annual Meeting
Fecal Transfer from Mice on High or Low Magnesium Diets Confers Arthritis Protection
Teresina Laragione¹, Carolyn Harris ¹ and Percio Gulko ¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Magnesium (Mg) plays a key role in the immune response. We have previously demonstrated that alterations in the Mg balance by increasing or decreasing…
Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting
Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Mochihito Suzuki¹, Toshihisa Kojima ², Nobunori Takahashi ², Shuji Asai ² and Naoki Ishiguro ², ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
Abstract Number: 1999 • 2019 ACR/ARP Annual Meeting
NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion
Ha-Reum Lee¹, Su-Jin Yoo ², Chan-Geol Park ², Jinhyun Kim ², In Seol Yoo ² and Seong Wook Kang ², ¹Chungnam National University Hospital,, Daejeon, Republic of Korea, ²Chungnam National University Hospital, Daejeon, Republic of Korea
Background/Purpose: Fibroblast-like synoviocytes (FLS) are key effector cells in the pathogenesis of rheumatoid arthritis (RA) through the increased cell migration, degradation of extracellular matrix, and…
Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
Abstract Number: 495 • 2019 ACR/ARP Annual Meeting
Pre-Rheumatoid Arthritis Diagnosis Prevalence of Commercial CCP Antibody Positivity Increases over Time with Strong Agreement Between Commercial Assays and Positivity Is Predicative of Developing Rheumatoid Arthritis Within 3 Years
Steven Taylor¹, Mark Parish ², LauraKay Moss ³, Marie Feser ⁴, Elizabeth Mewshaw ⁵, Jess Edison ⁵ and Kevin Deane ⁴, ¹University of Colorado - Denver, Denver, CO, ²University of Colorado Denver, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁵Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Rheumatoid arthritis (RA) related autoantibodies, in particular antibodies to citrullinated proteins (ACPA), predict likelihood of developing future RA. Indeed, clinical trials for RA prevention…
Abstract Number: 531 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis
Anita Kass¹, Hans Christian Gulseth ¹ and Camilla Zettel ¹, ¹Betanien Hospital, Skien, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and additional therapeutic approaches are needed. The improvement of RA disease activity during pregnancy, and flares during the…
Abstract Number: 985 • 2019 ACR/ARP Annual Meeting
Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis
Tomohiro Koga¹, Tomohito Sato ², Yushiro Endo ¹, Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Nobuya Yoshida ⁴, Masataka Umeda ⁵, George Tsokos ⁴ and Atsushi Kawakami ⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Background: CD4 + T cells are important in the pathogenesis of rheumatoid arthritis (RA), and therapies targeting the differentiation of osteoclasts are attracting attention. Calcium/calmodulin-dependent…
Abstract Number: 1400 • 2019 ACR/ARP Annual Meeting
Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis
Aniela Croiteru ¹, Merav Lidar ², Tatiana Reitblat³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Tanya Meshiach ⁵, Ronit Almog ⁵ and Ori Elkayam ⁶, ¹Tel Aviv medical center, Tel Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited. We sought to analyze…
Abstract Number: 2002 • 2019 ACR/ARP Annual Meeting
Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts
Samuel Finlay¹, Stefano Alivernini ², Aziza Elmesmari ³, Barbara Tolusso ², Luca Petricca ², Clara Di Mario ⁴, Annunziata Capacci ², Andrew Filer ⁵, Gianfranco Ferraccioli ², Iain McInnes ¹, Elisa Gremese ² and Mariola Kurowska-Stolarska ¹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, ⁵Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Background: A substantial proportion of Rheumatoid Arthritis patients do not respond to treatment and only a small proportion achieve sustained disease remission. We showed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].